Plasma brain natriuretic peptide: A biochemical marker of effective blood pressure management?

Journal of Hypertension

Volumn 27, Issue 2, 2009, Pages 425-432

  Andreadis, Emmanuel A ^a   Georgiopoulos, Dimitrios X ^a   Tzavara, Chara K ^a   Katsanou, Panagiota M ^a   Fragouli, Eleni G ^a   Mavrokefalou, Eugenia M ^a   Chatzis, Nikolaos A ^a   Ifanti, Georgia K ^a   Diamantopoulos, Emmanuel J ^a,b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Blood pressure control; Brain natriuretic peptide; Essential hypertension

Indexed keywords

ALBUMIN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADD ON THERAPY; ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES;

EID: 63849304645     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831997c2     Document Type: Article

References (29)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328.
2. Richards AM. Natriuretic peptides. Update on peptide release, bioactivity, and clinical use. Hypertension 2007; 50:25-30.
3. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509-516.
4. Vickery S, Price Ch, John I, Abbas N, Webb M, Kempson M, Lamb E. B-type natriuretic peptide (BNP) in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46:610- 620.
5. Kragelund Ch, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666-675.
6. Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Ristli J, et al. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 2004; 97:251-256.
7. Jakubik P, Janota T, Widimsky J, Zelinka T, Strauch B, Petrak O, et al. Impact of essential hypertension and primary aldosteronism on plasma brain natruretic peptide concentration. Blood Press 2006; 15:302-307.
8. Kato J, Eto T, Kitamura K, Eto T. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am J Hypertens 2005; 18:354-357.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., and the National High Blood Pressure Education Program Coordinating Committee. Seven Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
10. Devereux RP, Reicheck N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55:613-618.
11. Lucowicz TV, Fischer M, Hense HW, Doring A, Stritzke J, Riegger G, et al. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail 2005; 7:525- 531.
12. Friedwald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
13. Hainline A Jr, Karon G, Lippel K, editors. Manual of laboratory operations. 2nd ed. Lipid Research Clinics Program, Lipid and Lipoprotein Analysis, Washington DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1983.
14. Multicenter study of Tina-quant Albumin in urine and b-N- acetylglycosaminidase (b-NAG) in urine. Wien Klin Wschr 1991; 103 (Suppl 189):1-64.
15. Bibbins-Domingo K, Gupta R, Na B, Wu A, Schiller N, Wholley M. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events and mortality in patients with stable coronary heart disease. JAMA 2007; 297:169-176.
16. Association for the Advancement of Medical Instrumentation. American national standards for electronic and automated sphygmomanometers. Washington, DC: AAMI; 1987.
17. Andreadis EA, Tsourous GI, Marakomichelakis GE, Katsanou PM, Fotia ME, Vassilopoulos CV, Diamantopoulos EJ. High dose monotherapy vs. low dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005; 19:491-496.
18. Francis GS, Benedict C, Johnstone DE, Kirlinp C, Nickla J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
19. Yamamoto K, Burnett JC, Jougasaki M, Nishimura RA, Baihey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal market of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994.
20. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 1997; 96:3053-3062.
21. Irzmanski R, Banach M, Piechota M, Kowalski J, Barylski M, Cierniewski C, Pawlick L. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence of the selected morphological parameters. Clin Exp Hypertens 2007; 29:149-164.
22. Nilsson JC, Groenning BA, Nielsen G, Frits-Haasen T, Trewinski J, Hildebrandt PR, et al. Left ventricular remodelling in the first year after acute myocardial infraction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J 2002; 143: 696-702.
23. Freitag HM, Larson MG, Levy D, Benjamin EJ, Wang JT, Leip PR, et al. Plasma brain natriuretic levels and blood pressure in the Framingham Heart Study. Hypertension 2003; 41:978-983.
24. Dogan SM, Aydin M, Gursumer M, Dursum A, Murgan G, Onuk T. N-terminal probrain natriuretic peptide predicts altered circardian variation in essential hypertension. Coron Artery Dis 2007; 18: 347-352.
25. Tekes S, Cikim AS. The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. J Hum Hypertens 2007; 21:546-550.
26. Nakatsu T, Shinohata R, Mashima K, Yoko Y, Nishitani A, Toyonaga S, et al. Use of plasma B-type natriuretic peptide level to identify asymptomatic hypertensive patients with abnormal diurnal blood pressure variation profiles: nondippers, extreme dippers, and risers. Hypertens Res 2007; 30:651-658.
27. Brunner F, Wolkart G. Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res 2001; 51:577-584.
28. Lim HS, Patel JV, Nadar S, Hughes E, Lip GH. Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. Am J Cardiol 2005; 95:905- 908.
29. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50:325-332.